

Supplementary table 1 Predictors for recurrence-free survival on univariate and multivariate analyses

	Univariate analysis		Multivariate analysis	
	HR (95%CI)	<i>P</i> value	HR (95%CI)	<i>P</i> value
Male (<i>vs</i> female)	0.65 (0.33–1.29)	0.220		
Age (per 1 year increase)	1.04 (1.01–1.08)	0.009	1.05 (1.01–1.08)	0.009
SCC (<i>vs</i> AC)	1.92 (0.99–3.73)	0.053	1.13 (0.52–2.47)	0.753
Neoadjuvant + (<i>vs</i> neoadjuvant –)	2.67 (1.42–5.00)	0.002	2.27 (1.11–4.65)	0.025
Adjuvant + (<i>vs</i> adjuvant –)	2.16 (1.13–4.14)	0.020	2.05 (0.99–4.23)	0.052
Transthoracic approach (<i>vs</i> transhiatal approach)	1.67 (0.90–3.11)	0.104		
pStage III/IV (<i>vs</i> pStage I/II)	6.98 (3.20–15.23)	< 0.001	4.66 (2.03–10.68)	< 0.001

R1 (<i>vs</i> R0)	2.73 (1.20–6.17)	0.016	1.75 (0.72–4.26)	0.216
Anastomotic leakage	2.64 (0.93–7.45)	0.068	4.40 (1.41–13.75)	0.011
Postoperative pneumonia	1.97 (0.77–5.07)	0.160		

P: Pathologic; SCC: Squamous cell carcinoma; AC: Adenocarcinoma; R0: No residual tumor; R1: Microscopic residual tumor.

Supplementary table 2 Risk factors for anastomotic leakage on univariate and multivariate analyses

	Univariate analysis		Multivariate analysis	
	HR (95%CI)	<i>P</i> value	HR (95%CI)	<i>P</i> value
Male (<i>vs</i> female)	0.80 (0.15–4.21)	0.792		
Age (per 1 year increase)	0.94 (0.89–1.01)	0.106		
SCC (<i>vs</i> AC)	2.25 (0.50–10.08)	0.289		
Neoadjuvant + (<i>vs</i> neoadjuvant –)	1.76 (0.40–7.82)	0.458		
Adjuvant + (<i>vs</i> adjuvant –)	1.19 (0.23–6.25)	0.840		
Transthoracic approach (<i>vs</i> transhiatal approach)	1.65 (0.39–6.94)	0.494		
Cervical reconstruction (<i>vs</i> intrathoracic reconstruction)	0.33 (0.07–1.51)	0.155		

Subtotal esophagectomy (vs lower esophagectomy)	2.08 (0.49–8.79)	0.319		
Total gastrectomy (vs proximal esophagectomy)	1.41 (0.32–6.24)	0.649		
Splenectomy (vs no splenectomy)	2.38 (0.44–12.97)	0.316		
Operating time (per 1 min increase)	1.00 (1.00–1.01)	0.090	1.00 (1.00–1.01)	0.232
Amount of bleeding (per 1 mL increase)	1.00 (1.00–1.01)	0.085	1.00 (1.00–1.01)	0.907
Tumor diameter (per 1 mm increase)	1.04 (1.01–1.08)	0.008	1.04 (1.01–1.08)	0.020
pStage III/IV (vs pStage I/II)	2.21 (0.50–9.70)	0.293		
R1 (vs R0)	1.49 (0.17–13.32)	0.724		

P: Pathologic; SCC: Squamous cell carcinoma; AC: Adenocarcinoma; R0: No residual tumor; R1: Microscopic residual tumor.